Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2004

View Archived Issues

Aplidin enters phase II for hematological malignancies

Combunox approved for short-term management of acute moderate/severe pain

Extended indication for Fludara oral in Europe

Submission of Aryplase BLA

Early atherosclerotic coronary calcification may be pathogen-induced

ZD-0473 effective in chemotherapeutic-resistant human colorectal cancer cell lines

Treatment with recombinant diabody and thalidomide promising in preclinical model of lymphoma

New interferon shows potent antiviral and proliferative efficacy

Putative melatonin receptor agonist promising for treatment of glaucoma

Preliminary data on the immunogenicity of ChimeriVax-Dengue vaccine

AVI-4126 reported to improve outcome in patients undergoing PCI

Edaravone shows promise in the reduction of infarct size after AMI

Clinical evidence for the antihypertensive effects of rosiglitazone in type 2 diabetes

MultiHance receives FDA approval

Atacand approved in Europe for treatment of chronic heart failure

Orathecin NDA action date delayed by new data

Reliant to market newly approved Omacor in U.S.

Four patents covering new treatments of cancer

Novartis temporarily withdraws European application for Prexige

New formulations of tegaserod claimed by Novartis

Novartis researchers prepare parenteral formulations of mycophenolic acid

Kissei describes SGLT inhibitors in patent literature

Takeda scientists prepare MCH receptor antagonists for obesity, depression, and anxiety

Antiinflammatory agents in early development at Minophagen for pain, arthritis, etc.

Agents for the treatment of arthritis claimed by Sumitomo

Sankyo researchers prepare and test PTP inhibitors

FDA approves new indication for Nexium

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...